|
Basic Characteristics of Mutations
|
|
Mutation Site
|
S219A |
|
Mutation Site Sentence
|
The percentage of patients with sS210R/rtS219A was comparable between drug naïve HCC-patients (33.3%, 3/9) and drug-treated HCC-patients (35.7%, 5/14), thus excluding the impact of antiviral therapy on the selection of this mutation. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
X02763.1;X65259.1
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B, Chronic
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
28152517
|
|
Title
|
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
|
|
Author
|
Salpini R,Surdo M,Warner N,Cortese MF,Colledge D,Soppe S,Bellocchi MC,Armenia D,Carioti L,Continenza F,Di Carlo D,Saccomandi P,Mirabelli C,Pollicita M,Longo R,Romano S,Cappiello G,Spano A,Trimoulet P,Fleury H,Vecchiet J,Iapadre N,Barlattani A,Bertoli A,Mari T,Pasquazzi C,Missale G,Sarrecchia C,Orecchini E,Michienzi A,Andreoni M,Francioso S,Angelico M,Verheyen J,Ceccherini-Silberstein F,Locarnini S,Perno CF,Svicher V
|
|
Journal
|
Oncotarget
|
|
Journal Info
|
2017 Feb 28;8(9):15704-15715
|
|
Abstract
|
BACKGROUND: An impaired HBsAg-secretion can increase HBV oncogenic-properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. METHODS: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. RESULTS: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P <0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26+/-13%; P203Q+S210R:29+/-14%; wt:18%+/-9, P <0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26+/-8% for wt versus 33+/-6% for S210R, P <0.001). CONCLUSIONS: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.
|
|
Sequence Data
|
-
|
|
|